BioPharma Dive - Latest News

Roche broadens obesity drug plans with $1.65B Zealand deal

The deal gives the Swiss pharma access to an experimental amylin-targeting treat...

A new obesity biotech launches; Gilead plans to quickly...

Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs ...

Roche broadens obesity drug plans with $1.7B Zealand deal

The deal gives the Swiss pharma access to an experimental amylin-targeting treat...

Flagship startup raises $200M in pursuit of ‘scientific...

Funded by investors such as Flagship and General Catalyst, the AI startup claims...

Ono pays $280M to license Ionis rare disease drug

Ionis’ drug, sapablursen, is currently being tested in a Phase 2 trial in patien...

Healthcare tackles AI oversight with no aid from Trump ...

The president’s deregulatory agenda will mean more responsibility rests on healt...

Viking inks CordenPharma deal to boost obesity drug supply

The biotech will commit $150 million to an alliance that hands it significant pr...

Merck opens $1B vaccine plant in North Carolina

Unveiling of the new factory comes as Merck and other pharma companies face pres...

Arvinas gets positive breast cancer data, but finds dif...

Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing...

2seventy bio, Bluebird’s cell therapy spinout, sells to...

The deal ends 2Seventy’s short run as an independent company, during which it re...

2Seventy bio, Bluebird’s cell therapy spinout, sells to...

The deal ends 2Seventy’s short run as an independent company, during which it re...

Beam base editing therapy gets ‘proof of concept’ in ra...

While initial study results suggest Beam's technology can correct alpha-1 antitr...

Novo’s Wegovy successor disappoints in second large trial

A study in people with obesity and diabetes again found CagriSema helps people l...

Mineralys shares climb on study data for blood pressure...

Findings from a pair of studies in tough-to-treat hypertension establish Mineral...

3 ways to accelerate development and de-risk cell and g...

Development strategies designed to reduce the unknowns so that cell and gene the...

SynWeave™: Revolutionizing biopharma manufacturing by i...

Enhancing manufacturability is crucial for reducing the risks associated with sc...

J&J scraps depression testing for potential blockbuster...

Analysts say the decision is a “big blow” to a once-promising class of brain the...

Walgreens to be acquired in $10B take-private deal

The struggling retail pharmacy chain entered an agreement to be purchased by pri...

Roche launches new Boston center; NIH centralizes peer ...

The Swiss pharma will base cardiometabolic drug research at the new Allston site...

Nimbus swaps CEOs and turns to new leader for ‘next cha...

CBO Abbas Kazimi will replace longtime CEO Jeb Keiper as part of a planned leade...

Vertex’s new pain drug gets first coverage nod from maj...

Optum, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx...

Following FDA cuts, Trump nominee Makary vows ‘independ...

The Johns Hopkins surgeon highlighted rapid growth at the agency, but pledged ke...

Makary, under review to run FDA, evades pressure to rei...

Questioned by senators at a Thursday hearing, President Trump's FDA nominee said...

Federal judge extends block on Trump plan to limit NIH ...

A District Court judge issued a nationwide preliminary injunction against the ad...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.